Cargando…

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C

Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemura, Kazuya, Takizawa, Etsuko, Tamori, Akihiro, Nakamae, Mika, Kubota, Hiroshi, Uchida-Kobayashi, Sawako, Enomoto, Masaru, Kawada, Norifumi, Hino, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350226/
https://www.ncbi.nlm.nih.gov/pubmed/32630450
http://dx.doi.org/10.3390/ijms21124517
_version_ 1783557222159089664
author Takemura, Kazuya
Takizawa, Etsuko
Tamori, Akihiro
Nakamae, Mika
Kubota, Hiroshi
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kawada, Norifumi
Hino, Masayuki
author_facet Takemura, Kazuya
Takizawa, Etsuko
Tamori, Akihiro
Nakamae, Mika
Kubota, Hiroshi
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kawada, Norifumi
Hino, Masayuki
author_sort Takemura, Kazuya
collection PubMed
description Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR HCC development within 3 years after antiviral treatment. We included 670 patients with HCV who received direct-acting antivirals, achieved SVR and were followed up for at least 6 months (270 of them were followed up for 3 years or more). We measured serum ATX levels before treatment and 12/24 weeks after treatment. The diagnosis of HCC was based on imaging modalities, such as dynamic computed tomography and dynamic magnetic resonance imaging and/or liver biopsy. The present study revealed that high levels of serum ATX predicted post-SVR HCC development (area under the receiver operating characteristic: 0.70–0.76). However, Wisteria floribunda agglutinin positive Mac-2 binding protein (M2BPGi), another liver fibrosis marker, was a more useful predictive marker especially post-treatment according to a multivariate analysis. Patients with a high rate of ATX reduction before and after antiviral treatment did not develop HCC regardless of high pretreatment ATX levels. In conclusion, post-treatment M2BPGi level and the combination of pretreatment ATX levels and rate of ATX reduction were useful predictive markers for post-SVR HCC development in patients with chronic HCV infection.
format Online
Article
Text
id pubmed-7350226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73502262020-07-15 Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C Takemura, Kazuya Takizawa, Etsuko Tamori, Akihiro Nakamae, Mika Kubota, Hiroshi Uchida-Kobayashi, Sawako Enomoto, Masaru Kawada, Norifumi Hino, Masayuki Int J Mol Sci Article Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR HCC development within 3 years after antiviral treatment. We included 670 patients with HCV who received direct-acting antivirals, achieved SVR and were followed up for at least 6 months (270 of them were followed up for 3 years or more). We measured serum ATX levels before treatment and 12/24 weeks after treatment. The diagnosis of HCC was based on imaging modalities, such as dynamic computed tomography and dynamic magnetic resonance imaging and/or liver biopsy. The present study revealed that high levels of serum ATX predicted post-SVR HCC development (area under the receiver operating characteristic: 0.70–0.76). However, Wisteria floribunda agglutinin positive Mac-2 binding protein (M2BPGi), another liver fibrosis marker, was a more useful predictive marker especially post-treatment according to a multivariate analysis. Patients with a high rate of ATX reduction before and after antiviral treatment did not develop HCC regardless of high pretreatment ATX levels. In conclusion, post-treatment M2BPGi level and the combination of pretreatment ATX levels and rate of ATX reduction were useful predictive markers for post-SVR HCC development in patients with chronic HCV infection. MDPI 2020-06-25 /pmc/articles/PMC7350226/ /pubmed/32630450 http://dx.doi.org/10.3390/ijms21124517 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Takemura, Kazuya
Takizawa, Etsuko
Tamori, Akihiro
Nakamae, Mika
Kubota, Hiroshi
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kawada, Norifumi
Hino, Masayuki
Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
title Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
title_full Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
title_fullStr Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
title_full_unstemmed Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
title_short Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
title_sort post-treatment m2bpgi level and the rate of autotaxin reduction are predictive of hepatocellular carcinoma development after antiviral therapy in patients with chronic hepatitis c
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350226/
https://www.ncbi.nlm.nih.gov/pubmed/32630450
http://dx.doi.org/10.3390/ijms21124517
work_keys_str_mv AT takemurakazuya posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT takizawaetsuko posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT tamoriakihiro posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT nakamaemika posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT kubotahiroshi posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT uchidakobayashisawako posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT enomotomasaru posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT kawadanorifumi posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc
AT hinomasayuki posttreatmentm2bpgilevelandtherateofautotaxinreductionarepredictiveofhepatocellularcarcinomadevelopmentafterantiviraltherapyinpatientswithchronichepatitisc